Ovarian Cancer Diagnostic Market to Hit Sales of $2.35

Westford,USA, Oct. 12, 2022 (GLOBE NEWSWIRE) — Ovarian cancer is the 8^th most common cancer in women and the leading cause of death from gynecologic malignancies across the globe. As per WHO, more than 313,000 women are diagnosed with the cancer each year across the Global Ovarian Cancer Diagnostic Market. Wherein, it is the 5^th most common cancer in US women and affects more than 22,000 women and more than 14,000 women die from the disease per annum.

These statistics are alarming, but they’re not surprising. Ovarian cancer is notoriously difficult to detect in its early stages because it doesn’t cause any specific symptoms. This means that by the time a woman is diagnosed, the disease has often progressed to a more advanced stage.

SkyQuest analysis found that there are several factors contributing to this problem. Firstly, physicians often don’t suspect ovarian cancer when women present with nonspecific symptoms like abdominal pain or bloating. Secondly, there is no effective screening test for ovarian cancer, so it can be hard to catch the disease at an early stage.

Our study on the global ovarian cancer diagnostic market suggests that transvaginal ultrasonography (TVUS) and CA-125 blood tests are the most common tests for screening and diagnostics of ovarian cancer. Other screening tests and symptoms that may be indicative of ovarian cancer include: pelvic exam, computed tomography (CT) scan, MRI, Duncan procedure, endometrial biopsy, pap smear, vaginal bleeding or discharge outside of menstruation, abdominal pain or bloating, urinary frequency or urgency, and fatigue.

Get sample copy of this report:

https://skyquestt.com/sample-request/ovarian-cancer-diagnostic-market

Lack of Awareness is the Major Setback for Ovarian Cancer Diagnostic Market

SkyQuest study found that there is a significant demand for ovarian cancer diagnostic testing among US women. Nearly 60% of respondents said they would be willing to undergo…